AstraZeneca reveals pricing strategy for Nexium, lower than Losec
AstraZeneca has surprised industry observers by announcing a pricingstrategy for Nexium (esomeprazole) which is lower than the cost of its predecessor, the blockbuster antiulcerant Losec/Prilosec (omeprozole).
The price of Nexium, following its first launch in Sweden on August 14, will be 12.80 kroner ($1.40) per 40mg tablet and 10.30 kroner per 20mg tablet. This compares to 14.30 kroner for the price of each Losec multiple unit pellet system 20mg tablet.
The firm says that "in setting the price for Nexium in Sweden we have taken careful account of the pricing of competitive proton pump inhibitors and the desire to offer to doctors and patients incentives to use and benefit from the clinically superior Nexium. Consequently, Nexium 40mg has been priced at a small discount to Losec 20mg."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze